OnePeptideShip

Tesamorelin Research Profile

FDA Approved

Tesamorelin is an FDA-approved GHRH analog (brand name: Egrifta) with a hexenoyl group protecting it from DPP-4 degradation. It is uniquely effective at specifically mobilizing visceral (abdominal organ) fat while preserving lean muscle mass.

Tesamorelin Quick Technical Specifications

Category
Visceral Fat & GHRH
Elimination Half-Life
approx. 26 to 38 minutes
Storage Protocol
Refrigerated (2°C-8°C)
Status
FDA Approved
OE
Written by OnePeptideShip Editorial Team
Reviewed by Dr. Aris Thorne, MD, Board Certified Endocrinology Advisor
Updated September 2026

Mechanism of Action & Biochemical Context

Tesamorelin is an FDA-approved GHRH analog (brand name: Egrifta) with a hexenoyl group protecting it from DPP-4 degradation. It is uniquely effective at specifically mobilizing visceral (abdominal organ) fat while preserving lean muscle mass.

Storage, Reconstitution & Stability Guidelines

Prior to reconstitution, lyophilized Tesamorelin powder should be stored away from light between 2°C and 8°C for short-term access, or -20°C for long-term preservation. Once reconstituted with Bacteriostatic Water (0.9% benzyl alcohol preservative), maintain strict refrigeration between 2°C and 8°C. Do not freeze liquid solution.

Cited Scientific References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in HIV. N Engl J Med. 2007.
  2. Stanley TL, et al. Tesamorelin decreases liver fat and visceral adiposity in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2021.

Calculate Tesamorelin Syringe Units

Input your vial mg and BAC water mL to calculate exact U-100 draw units.

Open Tesamorelin Calculator →

Frequently Asked Questions

With 2mL of Bacteriostatic Water in a 10mg Tesamorelin vial, the concentration is 5mg/mL. A standard 1.0mg daily dose requires drawing 0.2mL, which is exactly 20 units on a U-100 syringe.

Tesamorelin stimulates very large pulses of endogenous Growth Hormone through its hexenoyl-protected GHRH mechanism. GH has a well-documented preferential lipolytic (fat-burning) effect on visceral adipose tissue (deep abdominal fat around organs) compared to subcutaneous fat. The large, sharp GH pulses from Tesamorelin appear to be particularly effective at mobilizing this metabolically dangerous fat depot.

Yes. Tesamorelin (brand name Egrifta, by Theratechnologies) has been FDA-approved since 2010 specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. This makes it one of the few research peptides with genuine FDA approval history, giving it a strong clinical safety profile.

All three are GHRH analogs, but their modifications differ. Sermorelin is the shortest fragment (29 amino acids) with the shortest half-life (~10 min). CJC-1295 is a modified 29-AA analogue with greater stability (~30 min half-life). Tesamorelin is the full 44-amino-acid sequence of human GHRH (the complete natural molecule) with a hexenoyl protection group, making it the most biologically complete and potent GHRH analog, with the strongest clinical trial data.

Yes, and this is a popular research combination. Ipamorelin suppresses somatostatin (the GH inhibitor) and activates the GHSR pathway, while Tesamorelin provides the GHRH signal. The combination produces a synergistic GH pulse significantly larger than either alone. For visceral fat research, this stack is considered one of the most potent non-HGH options available.

The FDA-approved clinical protocol for Tesamorelin runs for an indefinite period for HIV-lipodystrophy, but research protocols typically run 16-24 weeks, monitoring visceral fat via waist circumference or DEXA scanning. Meaningful changes in visceral fat are typically visible by week 8-12 in subjects who are also engaged in moderate caloric restriction.

Common Tesamorelin-specific side effects include: injection site reactions (redness, bruising, more common than with other peptides due to the higher active peptide dose per injection), fluid retention and joint stiffness (classic GH effects), and glucose tolerance changes (GH naturally creates mild insulin resistance; subjects with pre-diabetes should monitor blood glucose carefully).